This is great news for MNTA (as posted by iOwnSomeBio)-
The two companies have been in bruising competition to develop a generic version of low molecular weight heparin, currently a $4 billion per year blockbuster marketed by Sanofi Aventis under the name Lovenox.
"We've determined that there's no conflict here," Tyler said, adding that as an "act of good grace" Woodcock had stepped aside from any involvement in either company's application since August 2009.
Tyler also said that an investigation by the Department of Health and Human Services Inspection General has been dropped.
Tyler's statements, made in a telephone call to The Times, were greeted with disbelief by an Amphastar attorney, who noted that the company received a letter from the FDA in September declaring that Woodcock had no conflict of interest. {So SoLLy} :-)
Next in line - APPROVAL for MNTA
Market Data 
Markets 
AI
